Angiogenesis inhibition in metastatic hormone refractory prostate cancer (HRPC): A randomized phase II trial of two doses of the matrix metalloproteinase inhibitor (MMPI) BMS-275291
2004 ◽
Vol 22
(14_suppl)
◽
pp. 4647-4647
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 4647-4647
◽
2006 ◽
Vol 12
(5)
◽
pp. 1556-1563
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 4659-4659
2004 ◽
Vol 22
(14_suppl)
◽
pp. 4659-4659
2002 ◽
Vol 20
(5)
◽
pp. 1383-1388
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 4594-4594
2008 ◽
Vol 102
(9)
◽
pp. 1080-1085
◽
A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer
2004 ◽
Vol 10
(10)
◽
pp. 3365-3370
◽